0897.HK HKSE
Wai Yuen Tong Medicine Holdings Limited
1W: +1.4%
1M: +22.9%
3M: +38.9%
YTD: +1.4%
1Y: +15.4%
3Y: +33.7%
5Y: +108.1%
HK$0.38 ($0.05)
+0.01 (+1.35%)
Weekly Expected Move ±7.4%
HK$0
HK$0
HK$0
HK$0
HK$0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$745M
-4.9% ▼
5Y CAGR: +3.7%
Gross Profit
$376M
-4.7% ▼
5Y CAGR: +5.9%
Operating Income
-$32M
-177.5% ▼
Net Income
$7M
+146.2% ▲
5Y CAGR: -56.2%
EPS (Diluted)
$0.01
+148.5% ▲
5Y CAGR: -55.5%
EBITDA
$123M
+5.5% ▲
5Y CAGR: -27.7%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.4B | $1.3B | $784M | $745M |
| YoY Growth | +78.6% | +25.5% | -7.5% | -39.1% | -4.9% |
| Cost of Revenue | $660M | $817M | $677M | $389M | $369M |
| Gross Profit | $448M | $574M | $610M | $395M | $376M |
| Gross Margin | 40.4% | 41.3% | 47.4% | 50.4% | 50.5% |
| R&D Expenses | $5M | $1M | $2M | $2M | $1M |
| SG&A Expenses | $429M | $499M | $316M | $354M | $408M |
| Operating Expenses | $472M | $518M | $558M | $356M | $408M |
| Operating Income | -$23M | $56M | $52M | $41M | -$32M |
| Operating Margin | -2.1% | 4.0% | 4.0% | 5.2% | -4.3% |
| Interest Expense | $108M | $96M | $30M | $41M | $28M |
| Income Before Tax | -$308M | -$49M | -$15M | -$14M | $4M |
| Tax Expense | $148M | $41M | -$15M | -$6M | -$3M |
| Net Income | -$376M | -$109M | -$21M | -$15M | $7M |
| Net Margin | -33.9% | -7.8% | -1.6% | -2.0% | 1.0% |
| EPS (Diluted) | $-0.31 | $-0.09 | $-0.02 | $-0.01 | $0.01 |
| EBITDA | -$103M | $156M | $116M | $116M | $123M |
| Shares Outstanding | 1.23B | 1.23B | 1.22B | 1.18B | 1.13B |